(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.47%) $27.23
(0.41%) $924.25
(0.32%) $0.935
(0.80%) $11.04
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome...
Stats | |
---|---|
Today's Volume | 4 319.00 |
Average Volume | 7 646.00 |
Market Cap | 1.14B |
EPS | PLN-0.800 ( 2023-11-29 ) |
Last Dividend | PLN0 ( N/A ) |
Next Dividend | PLN0 ( N/A ) |
P/E | -12.32 |
ATR14 | PLN0.0620 (0.13%) |
Volume Correlation
Ryvu Therapeutics S.A. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Ryvu Therapeutics S.A. Correlation - Currency/Commodity
Ryvu Therapeutics S.A. Financials
Annual | 2023 |
Revenue: | PLN46.86M |
Gross Profit: | PLN-113.44M (-242.09 %) |
EPS: | PLN-4.02 |
FY | 2023 |
Revenue: | PLN46.86M |
Gross Profit: | PLN-113.44M (-242.09 %) |
EPS: | PLN-4.02 |
FY | 2022 |
Revenue: | PLN38.80M |
Gross Profit: | PLN21.40M (55.14 %) |
EPS: | PLN-4.57 |
FY | 2021 |
Revenue: | PLN11.19M |
Gross Profit: | PLN-2.54M (-22.69 %) |
EPS: | PLN-0.965 |
Financial Reports:
No articles found.
Ryvu Therapeutics S.A.
Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators